Review: Cholesterol-lowering treatment with statins reduces all-cause mortality in persons at risk: COMMENTARY

Rembold, Christopher
May 2006
ACP Journal Club;May/Jun2006, Vol. 144 Issue 3, p62
Academic Journal
The article presents comments of the author on a study which found that cholesterol-lowering treatment with statins reduces all-cause mortality in persons at risk. The meta-analysis by the Cholesterol Treatment Trialists' Collaboration confirms that lowering LDL cholesterol with statins significantly reduces coronary heart disease mortality, myocardial infarction stroke and coronary revascularization without increasing nonvascular mortality or cancer incidence. Clinical trials showing that statins are superior to other lipid-lowering therapies do not exist.


Related Articles

  • Review: Cholesterol-lowering treatment with statins reduces all-cause mortality in persons at risk.  // ACP Journal Club;May/Jun2006, Vol. 144 Issue 3, p62 

    The article discusses a study which found that cholesterol-lowering treatment with statins reduces all-cause and coronary heart disease mortality in persons at risk. Unconfounded randomized controlled trials (RCTs) that compared a statin with a control condition were chosen for the study. 14...

  • Oxidized low-density lipoprotein cholesterol and the ratio in the diagnosis and evaluation of therapeutic effect in patients with coronary artery disease. Huang, Huiling; Ma, R.; Liu, Dan; Liu, Chen; Ma, Yuedong; Mai, Weiyi; Dong, Yugang // Disease Markers;2012, Vol. 33 Issue 6, p295 

    Objective: The purpose of the present study was to investigate the value of ox-LDL and oxidation ratio of LDL (ox-LDL/TC, ox-LDL/HDL-C and ox-LDL/LDL-C) in diagnosis and prognosis evaluation in CAD patients. Also, we aimed to observe the effect of statins on reducing level of ox-LDL and...

  • Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. Cannon, Christopher P.; Braunwald, Eugene; McCabe, Carolyn H.; Rader, Daniel J.; Rouleau, Jean L.; Belder, Rene; Joyal, Steven V.; Hill, Karen A.; Pfeffer, Marc A.; Skene, Allan M. // New England Journal of Medicine;4/8/2004, Vol. 350 Issue 15, p1495 

    Background: Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear. Methods: We enrolled 4162 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and...

  • STRESS FROM CRP vs. LDL AND INFLAMMATION. Rosch, Paul J. // Health & Stress;Oct2010, Issue 10, p1 

    The article discusses health problems including heart disease, stress and inflammation. It notes that cholesterol and fatty foods do not cause heart attacks or coronary atherosclerosis likewise statins may benefit patients who have had a myocardial infarction. It states that some authorities...

  • Independent Nurse: Clinical CVD - Mixed results from latest research. Polak, Monika // GP: General Practitioner;12/9/2005, p105 

    This article presents results from trials investigating the treatment of heart diseases. Clinicians are familiar with the need to titrate up statins where possible to achieve maximum therapeutic benefit. A major international trial aimed to compare the cardiovascular risk reduction achievable...

  • Emerging Therapies and Their Role in Comprehensive Lipid Management. Vinall, Maria // MD Conference Express;Oct2011, p6 

    The article focuses on the clinical trials which aimed to evaluate low-density lipoprotein cholesterol (LDL-C) targets and assess their significance on treatment approaches. It mentions the result of the PROVE-IT trial which support intensive statin therapy after acute coronary syndrome (ACS),...

  • Atorvastatin Efficacy in the Prevention of Cardiovascular Events in Patients with Diabetes Mellitus and/or Metabolic Syndrome. Arca, Marcello // Drugs;2007 Supplement 1, Vol. 67, p43 

    Several large-scale clinical trials have assessed the efficacy of atorvastatin in the primary and secondary prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. In primary prevention, CARDS (Collaborative Atorvastatin Diabetes Study) showed that...

  • Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease. Hu, M.; Mak, V. W. L.; Chu, T. T. W.; Waye, M. M. Y.; Tomlinson, B. // Current Pharmacogenomics & Personalized Medicine;2009, Vol. 7 Issue 1, p1 

    The statins are the most important group of drugs for lipid-lowering therapy in the prevention of coronary heart disease. Greater reductions in LDL-cholesterol appear to be associated with greater benefits but the clinical efficacy and safety of statin treatment varies considerably from person...

  • New Cholesterol Guidelines Suggest Wider Use of Statins. Bond, Daniel // Access;Sep/Oct2004, Vol. 18 Issue 8, p4 

    Presents a study on the role of statins, a class of lipid-lowering drug, in reducing the incidence of heart disease, stroke and high cholesterol. Need of patients at high risk for heart failure to reduce their cholesterol levels; Details on the anti-inflammatory and antioxidant properties of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics